Iambic Presents Updated IAM1363 Clinical Data at ESMO 2026, Showing Durable Responses with a Favorable Tolerability Profile in Heavily Pretreated Participants with HER2-Driven Cancers
Iambic presented updated Phase 1/1b data for IAM1363, its AI-discovered brain-penetrant HER2 TKI, at the ESMO 2026 congress in Madrid. In heavily pretreated patients with targetable HER2 alterations dosed at >=960 mg QD, best overall response was 36% systemically (19/53) and 41% intracranially (9/22), including confirmed intracranial partial responses in three HER2-positive breast cancer patients previously treated with T-DXd and tucatinib. Tolerability was favorable: grade 3 TRAEs and TRAE-driven dose modifications each occurred in 5.9% of patients at the recommended dose, with no grade 4 or 5 TRAEs; more than half of 960 mg patients remain on study, some beyond one year.
Key figures
- Drug Name
- IAM1363
- Phase Of Trial
- Phase 1/1b
- Data cutoff
- 2026-08-31
- Systemic pr
- 36% (19/53)
- Intracranial pr
- 41% (9/22)
- Grade3 trae rate
- 5.9%
- Recommended dose
- 960 mg QD
- Participants dosed
- 122
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.